Doxorubicin

Where the papers sit

91 papers from the last 6 months study doxorubicin directly · updated from PubMed 12 Oct 2026

• Responsive Cancer Drug Delivery

  Cancer delivery systems are shifting toward local, targeted and stimulus-responsive release rather than passive drug exposure. pH, glutathione, lactate, heat and enzyme triggers recur across nanogels, prodrugs, microneedles, liposomes and polymer conjugates. Hyaluronic acid, folate and zwitterionic coatings are used to improve tumor uptake, circulation and biocompatibility. Deep penetration, controlled release kinetics and reduced immunogenicity remain the main performance goals.

  27 papers · 29.7%

• Chemotherapy Resistance in Cancer

  Multifunctional nanoparticles and micelles are being designed to overcome drug-resistant tumors through co-delivery and tumor or stroma targeting. Immunostimulatory oligonucleotides, ultrasound, photothermal therapy and chemodynamic therapy are recurring combination approaches. Resistance is associated with TGF-β2–HMGB1 autophagy, endothelial angiocrine signaling and altered tumor penetration. Evidence spans breast, colon, ovarian, bladder, liver, nasopharyngeal and bone cancers, limiting a single dominant mechanism.

  20 papers · 22%

• Nanotherapy in Breast Cancer

  Targeted exosomes, lipid carriers, hydrogels and magnetic nanoparticles are being developed for breast-cancer drug delivery. Combination strategies add photothermal, immune, peptide or metformin treatment to improve cytotoxicity and systemic exposure. Triple-negative models recur, with 2D, 3D and resistant systems testing treatment depth. Paxillin, membrane remodeling, tunnelling nanotubes, autophagy and miR-21 emerge as resistance-related targets.

  16 papers · 17.6%

• ROS-Enabled Cancer Therapy

  ROS-amplifying nanomedicines are being used to intensify chemotherapy, photothermal therapy and ferroptosis. Nanozymes, nitric oxide systems and ROS-responsive carriers aim to generate toxic species selectively in tumors. Several designs pair improved delivery with membrane disruption or multidrug-resistance reversal. Pyroptosis regulation also addresses the tension between antitumor efficacy and cardiotoxicity.

  13 papers · 14.3%

• Cardiotoxicity and Cellular Senescence

  Cardiotoxicity is being linked to oxidative stress, mitochondrial injury, inflammation and premature senescence. Shikonin, luteolin, HDAC inhibition and Huangqi Guizhi Wuwu Decoction are explored as protective strategies. METTL3 targeting and CDKN1A suppression connect endothelial senescence with vascular disease. The field is moving toward redox and mitochondrial protection without sacrificing antitumor activity.

  7 papers · 7.7%

• Others — Glioblastoma Drug Delivery

  Glioblastoma delivery is moving toward exploiting postoperative blood–brain barrier disruption and active transport through transferrin or ferritin systems. Nanomotors, oxygen-generating particles and targeted nanoparticles seek deeper penetration and stronger chemo-radiotherapy responses. Spheroid and microphysiological models are being used to test penetration and treatment response. A minority of papers instead concerns hepatoblastoma, hepatoma or pain control, making the cluster only partly unified.

  8 papers · 8.8%